Continues verses intermittent oral iron therapy in pregnant women

Impact of continuous verses intermittent oral iron therapy on blood indices , iron profile and fetomaternal outcome - Nil

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070943

Enrollment

220

Registered

2024-07-22

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O990- Anemia complicating pregnancy, childbirth and the puerperium

Interventions

Intervention1: tab ferrous ascorbate intermittently: tab ferrous ascorbate 60mg biweekly twice a day for 18 weeks Control Intervention1: Tab ferrous ascorbate continuously: tab ferrous ascorbate 60mg

Eligibility

Inclusion criteria

Inclusion criteria: antenatal women coming to OPD between gestational age 12 - 18 weeks.

Exclusion criteria

Exclusion criteria: twin pregnancy moderate and severe anaemia gestational diabetes

Design outcomes

Primary

Measure	Time frame
maternal hemoglobin and iron profileTimepoint: Two years	—

Secondary

Measure	Time frame
fetal outcome and maternal outcomeTimepoint: two years	—

Countries

India

Contacts

Public ContactShazia Parveen

JNMCH, Aligarh Muslim University, Aligarh

shzparveen@gmail.com8218578373

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026